Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®PRNewsWire • 03/12/24
Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®PRNewsWire • 03/06/24
Invitation to the presentation of Calliditas´ Year-end report January - December 2023PRNewsWire • 02/14/24
Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium CapitalPRNewsWire • 12/27/23
Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney functionPRNewsWire • 12/20/23
Calliditas Receives Notice of Allowance for United States Patent Application Covering TARPEYO®PRNewsWire • 12/11/23
Calliditas Therapeutics: Undervalued Rare Disease Commercial Stage Biotech (Maintaining Buy)Seeking Alpha • 11/27/23
Calliditas' partner Everest Medicines announces China NMPA's approval of Nefecon® for the treatment of primary IgA nephropathyPRNewsWire • 11/24/23
Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023PRNewsWire • 11/07/23
New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA NephropathyPRNewsWire • 10/27/23
Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023PRNewsWire • 10/19/23